CureVac is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA). Co.'s product portfolio includes clinical and preclinical candidates in prophylactic vaccines, oncology and molecular therapy. In prophylactic vaccines, Co. is developing its mRNA vaccine candidate, CV2CoV against coronavirus (SARS-CoV-2) in collaboration with GlaxoSmithKline Biologicals SA. CV2CoV is a representative of its COVID-19 vaccine program. The vaccine candidate is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles. The CVAC average annual return since 2020 is shown above.
The Average Annual Return on the CVAC average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CVAC average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CVAC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|